We report the results of a single-center analysis of a cohort of 39 patients treated between 1997 and 2016 for transplantion-associated
thrombotic microangiopathy. We evaluated 2 subgroups of patients: 24 patients treated between 1997 and 2014 who received conventional
therapy and 15 patients treated with the
complement-inhibiting
monoclonal antibody eculizumab between 2014 and 2016. The conventional therapy group was treated predominantly with
defibrotide alone or in combination with
plasmapheresis or
rituximab. Despite an initial response rate of 61%, only 4 patients (16%) were long-term survivors, 2 of whom had a low-risk
thrombotic microangiopathy without multiorgan damage. Progression of thrombotic micorangiopathy and bacterial/
fungal infections contributed equally to treatment failure. The overall response rate in the
eculizumab group was significantly higher, at 93%. In addition, we were able to stop
eculizumab treatment in 5 patients (33%), all of whom had high-risk
thrombotic microangiopathy, due to sustained recovery. Despite the very good response in the
eculizumab-treated group, we did not observe a significant improved overall survival, due primarily to a high rate of
infection-related mortality (70%). Therefore, further studies are needed to identify the optimal therapeutic management approach for
transplantation-associated
thrombotic microangiopathy to improve its dismal outcome.